ELVN as reported
- Net Income
- −$106M
Net Income · +5.7% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$67M
Free Cash Flow · −5.3% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.67
EPS · −17% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$106M | +5.7% | Q2 2026 |
| EPS | −$1.67 | −17% | Q2 2026 |
| ROE | −19% | n/a | Q2 2026 |
| ROA | −19% | n/a | Q2 2026 |
| Free Cash Flow | −$67M | −5.3% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Enliven Therapeutics, Inc. (ELVN) - Net IncomeNet IncomeEnliven Therapeutics, Inc. (ELVN)